Header image  
www.adipobiotech.com  
  

 
 
 
 
 
 

脂肪酸结合蛋白-4(Fatty Acid Binding Protein-4)和代谢综合症

脂肪酸结合蛋白-4FABP4,又叫脂肪细胞型脂肪酸结合蛋白(Adipocyte FABP), 属于 FABP 家族成员。 它有132个氨基酸残基,人和小鼠的氨基酸同源性是91%。 脂肪酸结合蛋白-4主要的表达合成部位是脂肪细胞和巨嗜泡沫细胞。其主要功能是作为脂质转运蛋白结合长链脂肪酸和维甲酸(视黄酸)。近年研究资料表明, 脂肪酸结合蛋白-4FABP4过表达,血浆含量增加可以反映代谢综合征的一个可靠生物标示物。
脂肪酸结合蛋白-4的检测可以通过酶联免疫、蛋白质印迹试剂盒。可以检测血清或血浆的样本。检测时样本可能需要稀释1-2倍。

Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study

BACKGROUND: Adipocyte-fatty acid binding protein (A-FABP), a major cytoplasmic protein in adipocytes, plays a central role in the development of diabetes and atherosclerotic cardiovascular disease in experimental animals. We have previously shown that A-FABP is present in the bloodstream and that its circulating levels correlate with metabolic risk factors in a cross-sectional study. In the present study, we further evaluated the prospective association of A-FABP with the metabolic syndrome (MetS) as defined by the updated National Cholesterol Education Program criteria. METHODS AND RESULTS: In the present study, 495 nondiabetic adults from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study were prospectively followed up for 5 years. The relationship of serum A-FABP with the MetS and its components was investigated. At baseline, high A-FABP levels were associated with the MetS (odds ratio, 4.0; 95% CI, 1.5 to 10.4; highest versus lowest sex-specific tertile, adjusted for age, body mass index, the homeostasis model assessment index for insulin resistance, C-reactive protein, and adiponectin, P=0.005). On long-term follow-up, subjects with higher baseline A-FABP levels had progressively worse cardiometabolic risk profile and increasing risk of the MetS. Among 376 subjects without the MetS at baseline, 50 had developed it at 5 years. Apart from the homeostasis model assessment index for insulin resistance (P=0.001), baseline A-FABP was the only independent predictor of the development of the MetS during the 5-year follow-up (odds ratio, 4.7; 95% CI, 1.8 to 11.9; highest versus lowest sex-specific tertile, P=0.001, adjusted for the homeostasis model assessment index for insulin resistance and body mass index). A-FABP was predictive of the MetS even after adjustment for each of its individual components. CONCLUSIONS: Circulating A-FABP predicts the development of the MetS independently of adiposity and insulin resistance.

Xu A, et al. Circulation. 2007 Mar 27;115(12):1537-43



Human AFABP / FABP-4 QCRat AFABP / FABP-4 QC


蛋白质印迹检测大鼠脂肪组织的脂肪酸结合蛋白4使用小鼠抗人脂肪酸结合蛋白4多克隆抗体,抗体说明书


蛋白质印迹检测大鼠脂肪组织的脂肪酸结合蛋白4使用小鼠抗人脂肪酸结合蛋白4多克隆抗体,抗体说明书

蛋白质印迹检测大鼠脂肪组织的脂肪酸结合蛋白4使用小鼠抗大鼠脂肪酸结合蛋白4多克隆抗体,抗体说明书

 



蛋白质印迹检测大小鼠脂肪组织的脂肪酸结合蛋白4使用兔抗人脂肪酸结合蛋白4多克隆抗体,抗体说明书


FABP4

免疫组化检测人腹腔白色脂肪组织使用兔抗脂肪型脂肪酸结合蛋白抗体

 

FABP4

免疫组化检测大鼠腹腔白色脂肪组织使用兔抗人脂肪型脂肪酸结合蛋白抗体
脂肪酸结合蛋白-4(人)酶联免疫试剂盒
标准曲线范围: 0.5 ~25 ng/ml
检测灵敏度:1 ng/ml
样本体积:100微升
样本稀释:10倍 (加入稀释后的样本浓度仍高于25ng/ml, 可能还要继续稀释一定的倍数)

 

 

电子信箱 Info@Adipobiotech.com
电话号码 010-81786624; 81786244


试剂盒名称 目录号 规格
价格(元)
脂肪酸结合蛋白-4(人)酶联免疫试剂盒 SK00030-01 96T
call
脂肪酸结合蛋白-4(人) 样本酶联免疫检测 S00030-01 80个起
call
脂肪酸结合蛋白-4(人)酶联免疫试剂盒 SK00030-02 96T
call
脂肪酸结合蛋白-4(人) 样本酶联免疫检测 S00030-02 80个起
call
Mice Anti-human FABP-4 Antibody A00030-01 50 ul
1500
脂肪酸结合蛋白-4(人)小鼠多抗 A00030-01 50 ul
200 USD
脂肪酸结合蛋白-4(人)单抗 A00030-04-100 100ug
2000
脂肪酸结合蛋白-4(人)单抗 A00030-03-100 100ug
2000
脂肪酸结合蛋白-4(人)单抗 A00030-09-100 100ug
1600
脂肪酸结合蛋白-4(人)兔多抗 A00030-06-50 50ul
1500
脂肪酸结合蛋白-4(人)兔多抗 A00030-06-100 100ul
2500
FABP-4 (Human), recombinant 00030-01-100 100 ug
350 USD
FABP-4 (Human), recombinant 00030-01-1000 1 mg
3000 USD
脂肪酸结合蛋白-4(人)重组蛋白 00030-01-10 10ug
500
脂肪酸结合蛋白-4(人)重组蛋白 00030-01-100 100ug
3500
脂肪酸结合蛋白-4(人)重组蛋白 00030-01-50 50ug
2200
FABP-4 (Rat), recombinant 00030-08-100 100ug
350 USD
FABP-4 (Rat), recombinant 00030-08-1000 1mg
3000 USD
脂肪酸结合蛋白-4(大鼠)重组蛋白 00030-08-10 10ug
400
脂肪酸结合蛋白-4(大 鼠)重组蛋白 00030-08-50 50ug
2200
脂肪酸结合蛋白-4(大鼠)重组蛋白 00030-08-100 50ug
3500
脂肪酸结合蛋白-4(大鼠)单抗 A00030-02-100 100ug
2000
脂肪酸结合蛋白-4(大鼠)单抗 A00030-09-100 100ug
2000
脂肪酸结合蛋白-4(大鼠)单抗 A00030-10-100 100ug
2000
脂肪酸结合蛋白-4(大鼠)单抗 A00030-11-100 100ug
2000
脂肪酸结合蛋白-4(大鼠)单抗 A00030-12-100 100ug
2000
脂肪酸结合蛋白-4(大鼠)单抗 A00030-13-100 100ug
2000
Mice Anti-FABP-4 (Rat) Antibody A00030-07 50 ul
200 USD
小鼠抗脂肪酸结合蛋白-4(大鼠)抗体 A00030-07 50 ul
1500
Anti-FABP-4 (Rat) rabbit Antibody A00030-08 50 ul
200 USD
家兔抗脂肪酸结合蛋白-4(大鼠)抗体 A00030-08 50 ul
1000
脂肪酸结合蛋白-4(小鼠)重组蛋白 00030-03-25 25ug
1100
脂肪酸结合蛋白-4(小鼠)重组蛋白 00030-03-50 50ug
1800
脂肪酸结合蛋白-4(小鼠)重组蛋白 00030-03-100 100ug
2800
脂肪酸结合蛋白-3(人)重组蛋白 00030-05-10 10ug
800
脂肪酸结合蛋白-3(人)重组蛋白 00030-05-50 50ug
1800
脂肪酸结合蛋白-7(人)重组蛋白 00030-07-10 10ug
800
脂肪酸结合蛋白-7(人)重组蛋白 00030-07-50 50ug
1800

 

Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis

OBJECTIVE: Adipocyte fatty acid-binding protein (A-FABP) has been shown to be an important player in atherosclerosis in animal models. However, the clinical relevance of these findings is still unknown. This study aims to examine the relationship between serum A-FABP level and carotid intima-media thickness (IMT), an indicator of atherosclerosis in humans. METHODS AND RESULTS: The study cohort included 479 Chinese subjects who underwent carotid IMT measurement. Serum A-FABP levels were determined by enzyme-linked immunosorbent assays. Serum A-FABP levels positively correlated with carotid IMT in both men (r=0.211, P=0.001) and women (r=0.435, P<0.001). In women, but not in men, the presence of plaques was associated with significantly higher serum A-FABP levels (P<0.001 versus women without plaques). Stepwise multiple regression analysis showed that serum A-FABP level was independently associated with carotid IMT in women (P=0.034), together with age and hypertension (both P<0.001). CONCLUSIONS: A-FABP is an independent determinant of carotid atherosclerosis in Chinese women, but not in men. This gender difference may be attributed to the lower serum A-FABP levels in men, and the effect of other risk factors, such as smoking, among our male participants. Our results have provided clinical evidence supporting the role of A-FABP in the development of atherosclerosis.
Yeung DC., et al.Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1796-802. Epub 2007 May 17.
Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes - a 10-year prospective study in Chinese. Objective Adipocyte fatty acid-binding protein (A-FABP) is abundantly expressed in adipocytes and plays a role in glucose homeostasis in experimental animals. We have previously shown that circulating A-FABP levels are associated with the metabolic syndrome, which confers an increased risk of type 2 diabetes (DM). Here we investigated whether serum A-FABP levels could predict the development of DM in a 10-year prospective study. Research Design and Methods Baseline serum A-FABP levels were measured with ELISA in 544 non-diabetic subjects, recruited from the Hong Kong Cardiovascular Risk Factor Prevalence Study cohort, who were followed prospectively to assess the development of DM. The role of A-FABP in predicting the development of DM over 10 years was investigated using Cox regression analysis. Results At baseline, serum sex-adjusted A-FABP levels were higher in subjects with impaired glucose tolerance or impaired fasting glucose (IGT/IFG) (p<0.00001 versus normal glucose tolerance) and correlated positively with adverse cardio-metabolic risk factors. Over 10 years, 96 subjects had developed DM. High baseline A-FABP was predictive of DM, independent of obesity, insulin resistance or glycemic indices (RR 2.25, 95%CI 1.40-3.65; p=0.001; above versus below sex-specific median). High A-FABP remained an independent predictor of DM in the high-risk IGT/IFG subgroup (adjusted RR 1.87, 95%CI 1.12-3.15, p=0.018). Conclusions Serum A-FABP was associated with glucose dysregulation and predicted the development of DM in Chinese.
Tso AW, et al. Diabetes Care. 2007 Jul 9; [Epub ahead of print]

 

 

 



 
脂肪因子的创新研究